Advancing Biomarker Discovery, Companion Diagnostics & IVD from Research to Commercialisation to Deliver Regulatory Compliant Diagnostic Tests for Patients in Oncology, Immunology & Beyond

April 23 - 25, 2024 | London, UK

Welcome to the 14th Clinical Biomarkers & CDx Europe

After 2 years of a maturing regulatory landscape for companion diagnostics and IVD in Europe, the emergence of new technologies including AI/ML, next generation sequencing and genetic-based diagnostics, coupled with a plethora of groundbreaking collaborations and CE-mark approvals, has led to an inflection point in which personalised medicines for all patients is now on the horizon in Europe.

As such the 14th Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the leading forum for drug developers, diagnostics providers, and regulatory professionals to accelerate the development of drug-diagnostics in diseases with unmet medical need. With a revamped track design, 2024 has 2 streams dedicated to: Biomarker Discovery & Development and Drug-Dx Development & Commercialisation to propel your development.

Join 180+ senior executives across Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics working on modalities such as gene therapy & protein degradation, and novel biomarkers such as cfDNA & circulating histones amongst many others, for an all-encompassing thought leadership meeting where you can walk away with actionable insights and meaningful connections to successfully co-develop a European regulatory compliant CDx based precision medicine drug to improve patient outcomes.

FREE FOR DRUG DEVLOPERS, RESEARCHERS & ACADEMICS

Take your seat in the room to:

7

Unearth how field-leading experts are navigating new European regulatory guidelines to enable the harmonious development of drugs and companion diagnostics to improve patient access to personalised medicines

9

Supercharge your biomarker discovery progress using advances in AI & machine learning to fully harness ‘big data’ across a plethora of disease indications

10

Leverage Biopharma experience to effectively and compliantly co-develop diagnostics alongside medicines in oncology, CNS, immunology, rare disease and beyond

8

Maximize patient access to diagnostics with detailed analysis of market access and reimbursement trends across European health authorities

 

A Snapshot of Our Expert Speaker Faculty

Hear What Previous Attendees have Said:

"Knowledgeable presenters and optionality to move between the 2 workstreams. Attendees were also very generous in providing insights!"

VP Global Regulatory Sciences, Bristol Myers Squibb

Favicon (6)
Untitled design (37)

"The Clinical Biomarkers & CDx Summit Europe brought a good mix of established vendors and new vendors offering more cutting-edge technologies. Very interesting technical presentation!"

Associate Director, Seagen

"Excellent networking opportunities thanks to sufficient Breaks. Good presentations on a sensitive topic that concerns the whole community. Great speakers!” 

Translational Medicine Scientist, Debiopharm

Untitled design (38)

Who Attended in 2023:

Copy of 41611 - company Splash (1)

2024 Partners

Expertise Partners

Program Partners

Spotlight Partners

Panel Partner